{"name":"SinoMab BioScience Ltd","slug":"sinomab-bioscience-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SM03","genericName":"SM03","slug":"sm03","indication":"Systemic lupus erythematosus (SLE)","status":"phase_3"}]}],"pipeline":[{"name":"SM03","genericName":"SM03","slug":"sm03","phase":"phase_3","mechanism":"SM03 is a monoclonal antibody that targets CD40 ligand (CD40L) to modulate immune responses and reduce inflammatory activation.","indications":["Systemic lupus erythematosus (SLE)","Autoimmune conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxQbkk4RVM2cUo5VGtyaWdnc3RMSG53bUlMbEtNb2dyZHcwWEd1M3BJaGIzclhvTzFhLUJXQlJlRXpLLS15bWN5MkRWMXE4YzNxX00tZEk5ZGp2ZWtkdUduUHV0eE9wY0p0Sm5DYzZNTHd4QjdWdS1lTU5UMVo3U0tKUEl4eE5DcmhkbXhXbGRMbmxXOFN0aVJXUl9wVlRwdTJfTnMzU1hoT0VBTG4xeFA3WW1UOFJNTEJ1VEpJMmFPNlN6SDBFWXJ0bGQwN0lRaDYxX2tQZl9XOXJ6ZGp4U3Vpby1mUDhmMzFrbVMwU01ycnlWZEh3NkVMSTN6SkEyc2lzRnpKeUVFSDRRc3N1WjV1WWxKOERXSkI1cmxjVmh0VndTWjRuTmNqM095cW1Jc2pVcUFRRkU4TGFjOXN3UlBianctbUxfb1NhMWF5Z1BR?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart","summary":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - B","headline":"Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"investingnews.com","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - investingnews.com","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPU3RGMlFjcVVhSnVqOE1mbUlPNEtjOEU2V1hlNG05czhRZ3B1MkZRY0pTTHR5UEFqQTlJUnYyOUI1N0lodDl5N1V2S1NRQ0VmdkdVVTRHa1hpTmVPeTZ3eUVlV1lFREV1ZlFkMmpPZkZ5WWFCSDFQSU8wdER1ZXI2R25LWl80Q3ZGVm9OU24xd2I0VENzcVlUc0NlUHhZektWNldUR01ZNUdlYTNyNV9uLUJvUjc5dXBDMU1YTTlYeFNPVVFSRHRPLUgxQVRFZ2tSVWpTVlk1MGg4WTdDTzBnVXh0NV9ELW5sVFlBNG5IdzJsX0JvWkZoRkx6eThJRHRZQmUxMXZkYlFnMzZCX1p3X2x6U3hEUE90eERTZmwyV1Fhd2R2a2lMT184UVMzckdjNFVscENEMUFzbjdJaUgyUzBYcG5SRUk3V0w4dWhBTVhNWVU?oc=5","date":"2025-03-31","type":"regulatory","source":"Barchart","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma Co. Ltd., Teijin Pharma -","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOdUpKN2tHcFo2OUZGMFNIR3dDYWhSSWtHb3YteUxXWmxqaEVCQ3dLQXRaeVpocnlucVdickJZVkZhVXN3Nnk1Y09DLW12TTRINThYTjNFMWFJWDRhbG45WHRlaU9TcWhtamc1NUhfbzlXVjRISDdDT3VsSWl5bEt6dQ?oc=5","date":"2023-05-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma - Pharmaceutical Technology","headline":"China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQSnlqLW50RXFXcmk1ekhya1BQMVdfS0hMUFNaNHJ3RWxtQmZOWlFDWC1PMzJ3YVNEYmtTUU1tR2U0OGgwSXhwYnZxM3RtMXdvU1dZbVU1b3Exb0I5eDVtYnU5RFJmeXpIZkxOQmtYNEU2SFNZa0ZyZGtPSzJnQ21mS2hnYmc4THJWZVBqdlRIQ2tFYVdfUnZ3LThUdXozLVFpcWhkd1FrNlFmN0EtRHU1RTNYbXVyZG5XZzNuRDk5T3RxMzhpcmk3ZURPOGMyNGtCYnFlOGIyenVhV1lLcjZ1S2g2UEtIZWxwOTl2VS1uUlZsbVMwalRqUW1aVE4zVmhUTXVIN1hiOTBPRnhiRHZmWTdQMTY0UlU5UzBoTWlVMjQ0SE9uYjBUbklsWmxLak9PVDIw?oc=5","date":"2023-04-27","type":"trial","source":"Media OutReach Newswire","summary":"SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis - Media OutReach Newswire","headline":"SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOeWwyTW80cHlXUk9sdG5uVzJla3gxUzdsRVNqTERWd3hfTXJwT1hSbEVkTDJad2hBM0VxcVlyZkxFU3VQV0R4bktaZWhnaEp6NkxIYnhsdjJsdVltRGxNUmg3NWRvQ2VmR3c2My1OVHJKZTJac3NNV3RuZTFOeGFNME5JOHFDT1NyUUlKLW1leC1MeWZwZDUwNjdzY3JjcHI0VkdWUkFDSGI4U2VhM0xfZjMzUGk3Uk0?oc=5","date":"2021-09-17","type":"pipeline","source":"Contract Pharma","summary":"Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact - Contract Pharma","headline":"Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}